- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
PolyPid (PYPD)
PolyPid stock price live, this page displays NASDAQ PYPD stock exchange data. View the PYPD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the PolyPid real time stock price chart below.
What Is the PolyPid Stock Price Today?
The PolyPid stock price today is 4.7400.
What Is the Stock Symbol for PolyPid?
The stock symbol for PolyPid is "PYPD."
What Stock Exchange Does PolyPid Trade On?
PolyPid is listed and trades on the NASDAQ stock exchange.
Is PolyPid a Good Stock to Buy?
Determining whether PolyPid—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PYPD quote. (ISIN: IL0011326795)
What Is the PolyPid Stock Price Today?
The PolyPid stock price today is 4.7400.
What Is the Stock Symbol for PolyPid?
The stock symbol for PolyPid is "PYPD."
What Stock Exchange Does PolyPid Trade On?
PolyPid is listed and trades on the NASDAQ stock exchange.
Is PolyPid a Good Stock to Buy?
Determining whether PolyPid—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PYPD quote. (ISIN: IL0011326795)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.6000
4.8100
52 wk Range
3.0600
5.7300
PYPD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.60004.8100
52 wk Range
3.06005.7300
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PYPD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
11.7500
Upside
+147.89%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.7500
(+147.89% Upside)
PolyPid Earnings Call Summary for Q2/2026
- PolyPid narrowed Q2 2026 loss to $7.8M ($0.35/share) from $10M ($0.78/share) YoY, beating estimates by 12.5%; shares fell 5.92% premarket to $4.45.
- FDA accepted D-PLEX100 NDA with priority review, setting PDUFA goal date of Nov. 28, 2026; European Medicines Agency submission planned for Q3 2026.
- Azurity Pharmaceuticals partnership secured $30M upfront with potential $290M+ in milestones; deal includes royalties and label-expansion funding.
- Cash position of $6.6M at June 30 plus Azurity proceeds expected to fund operations into 2028; early 2027 launch targeted if FDA approval obtained.
- Label expansion planned for cardiac surgery, orthopedic procedures, and breast reconstruction beyond initial abdominal surgery indication.
Last Updated: 2026/08/12, 15:26
Read Full TranscriptEarnings
Latest Release
Aug 12, 2026
EPS / Forecast
-0,35 / -0,40
Revenue / Forecast
-- / --
Compare PYPD to Peers and Sector
Metrics to compare | PYPD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPYPDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.1x | −0.6x | −0.4x | |
PEG Ratio | −0.05 | −0.01 | 0.00 | |
Price/Book | 17.9x | 0.6x | 2.6x | |
Price / LTM Sales | - | 6.3x | 3.1x | |
Upside (Analyst Target) | 163.7% | 928.8% | 48.3% | |
Fair Value Upside | Unlock | 6.1% | 6.2% | Unlock |
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the PolyPid (PYPD) Stock Price Today?
The PolyPid stock price today is 4,7400 USD.
What Stock Exchange Does PolyPid Trade On?
PolyPid is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for PolyPid?
The stock symbol for PolyPid is "PYPD."
What Is the PolyPid Market Cap?
As of today, PolyPid market cap is 96,2800M USD.
What Is PolyPid's Earnings Per Share (TTM)?
The PolyPid EPS (TTM) is -1,4762.
When Is the Next PolyPid Earnings Date?
PolyPid will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is PYPD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has PolyPid Stock Split?
PolyPid has split 1 times.
How Many Employees Does PolyPid Have?
PolyPid has 72 employees.
What is the current trading status of PolyPid (PYPD)?
As of Aug 16, 2026, PolyPid (PYPD) is trading at a price of 4,7400 USD, with a previous close of 4,7800 USD. The stock has fluctuated within a day range of 4,6000 USD to 4,8100 USD, while its 52-week range spans from 3,0600 USD to 5,7300 USD.
What Is PolyPid (PYPD) Price Target According to Analysts?
The average 12-month price target for PolyPid is 11,7500 USD, with a high estimate of 14 USD and a low estimate of 8 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +147,89% Upside potential.
What Is the PYPD After Hours Price?
PYPD's last after hours stock price is 4,7600 USD, the stock has decreased by 0,0200, or 0,4200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.